Galapagos receives transparency notification from EcoR1 Capital
September 30 2024 - 3:01PM
UK Regulatory
Galapagos receives transparency notification from EcoR1 Capital
Mechelen, Belgium; 30 September 2024, 22:01
CET; regulated information – Galapagos NV (Euronext & NASDAQ:
GLPG) received a transparency notification from EcoR1 Capital
LLC.
Pursuant to Belgian transparency
legislation1, Galapagos received a transparency
notification on 26 September 2024 on behalf of Mr. Oleg Nodelman
and EcoR1 Capital LLC, who notified us that EcoR1 Capital LLC holds
7,094,049 of Galapagos’ voting rights, consisting of 6,939,043
ordinary shares and 155,006 American Depository Receipts, further
to a conversion of financial instruments and an acquisition of
voting securities.
EcoR1 Capital LLC, controlled by Mr. Oleg
Nodelman, controls investment funds EcoR1 Capital Fund Qualified LP
and EcoR1 Capital Fund LP, which all together hold 7,094,049 of
Galapagos’ voting rights. This represents 10.77% of Galapagos’
currently outstanding 65,897,071 shares. On 20 September
2024, Ecor1 Capital LLC converted 5,873,868 American Depository
Receipts into ordinary shares. As a result, EcoR1 Capital LLC
crossed above the 10% threshold of Galapagos’ voting rights linked
to voting securities and the number of voting rights linked to
equivalent financial instruments crossed below the 5% threshold.
Between 11 September and 20 September 2024, EcoR1 Capital LLC
further acquired 225,787 ordinary shares and 154,709 American
Depository Receipts. The transparency notification further
specifies that (i) the 7,094,049 voting rights are beneficially
owned by clients of EcoR1 Capital Fund Qualified LP and EcoR1
Capital Fund LP and that these clients include, among others,
individuals, endowments, foundations and pooled investment
vehicles, and (ii) EcoR1 Capital LLC is the discretionary
investment advisory manager and exercises the voting rights of its
entities at its discretion in the absence of specific instructions.
The full transparency notification is available on the Galapagos
website.
About Galapagos
We are a biotechnology company with operations in Europe and the
U.S. dedicated to developing transformational medicines for more
years of life and quality of life. Focusing on high unmet medical
needs, we synergize compelling science, technology, and
collaborative approaches to create a deep pipeline of best-in-class
small molecules and cell therapies in oncology and immunology. With
capabilities from lab to patient, including a decentralized cell
therapy manufacturing network, we are committed to challenging the
status quo and delivering results for our patients, employees, and
shareholders. For additional information, please
visit www.glpg.com or follow us
on LinkedIn or X.
For further information, please
contact:
Media
inquiries:
Marieke Vermeersch
+32 479 490 603
media@glpg.com
Jennifer Wilson
+44 7444 896759
media@glpg.com |
Investor
inquiries:
Sofie Van Gijsel
+1 781 296 1143
ir@glpg.com
Sandra Cauwenberghs
+32 495 584 663
ir@glpg.com |
1 Belgian Act of 2 May 2007 on the
disclosure of major shareholdings in issuers whose shares are
admitted to trading on a regulated market and regarding
miscellaneous provisions, as amended from time to time.
- Galapagos receives transparency notification from EcoR1
Capital
Galapagos (TG:GXE)
Historical Stock Chart
From Nov 2024 to Dec 2024
Galapagos (TG:GXE)
Historical Stock Chart
From Dec 2023 to Dec 2024